(TheNewswire)
Calgary, Alberta – TheNewswire - August 12, 2021 – Voyageur PharmaceuticalsLtd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company"or "Voyageur") announced that it hasissued 200,000 options to directors pursuant to its incentive stockoption plan (the “Options”). In addition, the Company announces ithas issued 169,872 Deferred Share Units (“DSU’S”) to directorspursuant to its equity incentive compensation plan.
The grants referred to above are subject to approval ofthe TSX Venture Exchange ("TSXV"). The Company’s equityincentive compensation plan was adopted by the Company followingreceipt of approval by a majority of disinterested shareholders at theCompany’s AGM held on June 23, 2021. The incentive stock optionplan of the Company was also approved at this meeting.
About Voyageur
Voyageur Pharmaceuticals Ltd. is Canadian publiccompany listed on the TSXV under the trading symbol VM. Voyageur isfocused on the development of barite and iodine, Active PharmaceuticalIngredient (API) minerals. The near-term focus is developing bariumand iodine radio-contrast pharmaceutical products. Voyageur’s goalis to initially generate the positive cash flow from operations usingthird party GMP pharmaceutical manufacturers in Canada andinternationally. Ultimately, Voyageur has plans to build all therequired infrastructure to become 100% self-sufficient with allmanufacturing. Voyageur owns a 100% interest in three barium sulfate(barite) projects including two properties suitable in grade for theindustrial barite marketplace, with interests in a high-grade iodine,lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan ofbecoming the only fully-integrated company in the radiology medicalfield, by controlling all primary input costs under the mottoof: "From the Earth to the Bottle"
For Further Media Information or toset up an interview, please contact:
Brent Willis
President & CEO
Ron Love
CFO
T 403.818.6086
Forward Looking Information
This news release may contain certain forward-lookinginformation and statements, including without limitation, statementspertaining to receipt of TSXV approval for the grants describedherein, as well as statements relating to the development of bariumand iodine radio-contract pharmaceutical products, and statementsrelating to the Company's long term plans, including with respect tobecoming 100% self-sufficient with all manufacturing.. All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR website at www.sedar.com . Voyageurdoes not undertake to update any forward-looking information except inaccordance with applicable securities laws.
Reader Advisory
Neither the TSXV nor its Regulation Services Provider(as that term is defined in the policies of the TSXV) acceptsresponsibility for the adequacy or accuracy of this newsrelease.
NOT FOR DISTRIBUTION TO THE U.S.NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Copyright (c) 2021 TheNewswire - All rights reserved.